How to choose and validate the correct antibody for Western blot

Whether you're starting your thesis or setting up a new trial, this guide walks you through the decisions that really matter when choosing and validating an antibody for Western blot, in the order in which you should make them.

In this article

1. Start with your target and your sample, not the catalog
2. Verify that it is validated for Western blot
3. Host species and clonality
4. The secondary antibody, matching the primary one
5. Read the technical specifications and the literature critically.
6. Validate with controls: the part that is most often skipped
7. Optimize the protocol and handle the reagent well.
8. A good antibody needs a reproducible workflow

Start with your target and your sample, not the catalog

The most common mistake is opening the catalog before defining the experiment. The correct sequence is the opposite: first decide which region of the protein you want to detect and in which sample , and then search for the antibody.

Two basic checks:

• The immunogen must contain your region of interest. Antibodies are generated by immunizing animals with an immunogen (a complete protein, a fragment, a peptide, etc.), which is usually described in the product information. Verify that this immunogen matches the region of the protein you want to detect; sometimes it's not 100% detailed due to patent restrictions, but the available information should provide some guidance.
• Western blot uses reduced and denatured protein. This exposes linear epitopes that would otherwise be hidden by the secondary and tertiary structures. You need an antibody that recognizes the epitope in this state, not one that only works with the protein in its native conformation. Many Western blot antibodies require a reduced and denatured sample unless the product information specifies otherwise.

Verify that it is validated for Western blot

Never assume that an antibody that works in one application will work in all. An epitope perfectly accessible in another technique may be inaccessible in a Western blot sample precisely because it has been reduced and denatured. The fact that an antibody gives excellent results in another context says nothing about its behavior in your blot.

The data sheet is your primary source: it should list the applications in which it has been tested, the expected banding pattern, and, where available, specific batch data. If the manufacturer hasn't evaluated the antibody by Western blot, it doesn't necessarily mean it won't work, but you will have to validate it yourself from scratch.

Host species and clonality: two decisions that avoid surprises

Host species. The primary antibody must be generated in a species different from that of your sample. This prevents the secondary anti-immunoglobulin antibody from reacting with the sample's endogenous immunoglobulins. For example, to study a mouse protein, a rabbit primary antibody (followed by an anti-rabbit secondary antibody) is a good choice.

In Western blots, there's a practical nuance: if you're working with a cell lysate lacking IgG, this decision is less critical. However, tissue lysates and serum supernatants do contain immunoglobulins, and in small samples, IgG appears as two bands of 50 and 25 kDa (heavy and light chain). If your target falls near these weights, it's important to keep this in mind.

Clonality. The choice between monoclonal and polyclonal changes the type of outcome:

• Monoclonal antibodies: recognize a single epitope, provide low background, and yield very consistent results. However, they are not usually useful for detecting the target across multiple species.
• Polyclonal antibodies: these bind to multiple epitopes, amplifying the signal and better tolerating small variations in the antigen. The price is higher due to greater variability between batches.

The secondary antibody, matching the primary one

The secondary antibody is selected against the host species of the primary antibody: mouse primary → anti-mouse secondary, and so on. This offers a simple way to amplify the signal, because several secondary antibodies are combined with the same primary. Also, check that the secondary antibody is tested for your intended application and, in Western blots, that the conjugate (usually HRP for chemiluminescence detection) is compatible with your processing system.

Read the technical specifications and the literature critically.

Beyond validated applications, the data sheet contains time-saving information: immunogen description, epitope nature (if mapped), host species, isotype, cross-reactivity (proven or predicted by sequence homology), and recommended starting dilutions. Note that "predicted" cross-reactivity is only a prediction based on sequence similarity, not experimental data.

The literature is helpful, but with some nuances. Resources like PubMed or CiteAb show you which antibodies other groups use and under what conditions they have worked. However, buying "the most cited" antibody is no guarantee: a highly cited antibody in mouse tissue proves nothing in human tissue or your cell line. The citation proves it worked in that exact context, not in yours.

Validate with controls: the part that is most often skipped

Choosing well is half the job; the other half is validation. Without controls, you can't interpret your data with confidence. A minimum panel for Western blot analysis includes:

• Positive control: a recombinant protein or a lysate from a cell line that is known to express the target at detectable levels.
• Negative control: samples where the target is absent or reduced, for example lysates of cells treated with interfering RNA.
• Primary control: by incubating only with the secondary, you measure the background attributable to that secondary.
• Isotype control: an antibody of the same isotype but without specificity for the target, to identify the background provided by the primary.
• Titration: a dilution curve that defines your optimal working range before setting a single concentration. The dilution listed in the data sheet is rarely ideal for your specific matrix.
• Expected molecular weight: confirms that the band appears where it should. A strong signal at the wrong weight is not good news.

Optimize the protocol and handle the reagent well.

Every protocol needs fine-tuning. The most influential factors are the blocking buffer, the buffer in which you dilute the antibodies, the wash buffers, the duration and temperature of the incubations, and the detection method. Some primaries give a clean signal with a short incubation at room temperature; others perform much better overnight at 4°C. It's worth experimenting.

And don't neglect the handling of the antibody itself: consult the data sheet for proper reconstitution, storage, and aliquoting. Repeated freezing and thawing cycles degrade many IgG antibodies, so aliquoting on first use is not optional, it's routine.

A good antibody needs a reproducible workflow

There's one last piece that's often overlooked: no matter how well validated your antibody is, you can only trust what you see if the rest of the flow is consistent. If the migration pattern changes from gel to gel or the transfer is uneven, you'll never know if that extra band is real biology or an artifact of the process. Upstream reproducibility is what allows you to attribute what you see to the antibody, not the method.

That's where standardizing materials helps. GenScript's SurePAGE (Bis-Tris) precast gels offer batch-to-batch consistency and a reliable migration pattern, so your molecular weight readings are comparable across experiments. And in the steps involving the antibody itself, dedicated equipment makes all the difference: the automated eZwest™ Lite device handles blocking, incubation, and washing without intervention, so these steps are no longer dependent on who's on the bench that day.

In other words: choose and validate the antibody well, but give it a workflow that's up to par so that the effort is reflected in the results.